VolitionRX (VNRX)
:VNRX
Want to see VNRX full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.69Last Year’s EPS
-1.2Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented substantial scientific and commercial progress across multiple product pillars (Nu.Q Vet automation and feline assay, Nu.Q NETs publications and point-of-care finger-prick breakthrough, Capture-Seq >99% pure ctDNA claims, Nu.Q Discover expansion), alongside improving headline revenue (+300% YoY) and a stronger quarter-end cash balance driven by financing and grants. However, important caveats include revenue lumpiness driven in part by deferred recognition, rising operating expenses and cash burn, reliance on milestone payments and external financing, and the need for broader validation, publications, and regulatory/reimbursement approvals to convert technical advances into predictable commercial revenue. On balance, the call signals strong technical momentum and growing commercial interest but with execution and timing risks to monetize those advances in the near term.Company Guidance
Revenue Growth (YoY)
Revenue for Q1 FY2026 was approximately $1.0M versus $0.2M in Q1 FY2025, an increase of ~300% year-over-year, primarily driven by a $0.7M increase in deferred revenue recognition related to the Nu.Q Vet Heska agreement.
Improved Cash Position via Financing and Grants
Cash and cash equivalents rose to ~ $3.1M at quarter end from $1.1M at 31 Dec 2025 (up ~$2.0M, ~182%). Receipts included ~$5.4M net from ATM facility, ~$1.9M net from a convertible note, and ~ $1.0M of non-dilutive funding received (with ~$0.9M expected in tranches).
Operating Loss Slightly Improved
Management reported operating loss was 3% lower year-on-year despite higher operating expenses, reflecting progress on cost reduction and revenue recognition adjustments.
Nu.Q Vet: Automation & Feline Assay Milestone
Completed validation/verification of the chemiluminescent immunoassay (ChLIA) Nu.Q Vet test with Fujifilm Vet Systems in Japan enabling full central-lab automation (world first for the company). Feline prototype assay submitted for peer review detected 86% of feline lymphomas at 97% specificity; publication is expected to trigger a $5.0M contractual milestone payment.
Nu.Q NETs: Strong Clinical Publications and Point-of-Care Breakthroughs
Published Mayo Clinic trauma study (n=674) showing marked nucleosome elevations (H3.1: healthy 22.3 ng/mL → trauma 359.7 → VTE 828.4, ~37x healthy) supporting prognostic utility. DETECSEPS sepsis program is on track (first patient expected Q3). Demonstrated finger-prick lateral-flow detection of nucleosomes in capillary blood — a major technical milestone for point-of-care and low-resource settings.
Capture-Seq: High Purity ctDNA and Early Detection Results
Reported a novel 2-step CTCF Capture-Seq method producing >99% pure circulating tumor-derived DNA sequencing sets. Blinded validation cohort (n=81) showed detection of over 95% of Stage 1 and 2 colorectal and lung cancers in that set. Manuscript resubmitted and patents filed; strong inbound interest (preprint downloaded ~2,700 times).
Nu.Q Discover & rNuQ Webshop Commercial Expansion
Expanded collaborator network with a nonexclusive agreement with MBL in Japan; serving ~100 clients globally. Launched rNuQ webshop offering ISO 13485 manufactured recombinant nucleosomes as a new potential revenue stream.
Progress on Regulatory and Reimbursement Pathways
Clinical validation recruitment for Nu.Q Lung (Ulysses MAP) completed; IVDR-related documentation ahead of schedule and reimbursement dossier pre-submission activities underway with Hospices Civils de Lyon, aiming for potential clinical routine use in France late this year.
VNRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VNRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $2.20 | $2.00 | -9.09% |
Mar 31, 2026 | $4.04 | $4.00 | -0.99% |
Nov 13, 2025 | $7.09 | $6.62 | -6.61% |
Aug 14, 2025 | $12.88 | $13.90 | +7.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does VolitionRX (VNRX) report earnings?
VolitionRX (VNRX) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
What is VolitionRX (VNRX) earnings time?
VolitionRX (VNRX) earnings time is at Aug 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VNRX EPS forecast?
VNRX EPS forecast for the fiscal quarter 2026 (Q2) is -0.69.